Pay in 4 interest-free payments of $7.09 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
doi:10.1007/978-1-4899-1471-2_45 Franekova V, Angin Y, Hoebers NT, Coumans WA, Simons PJ, Glatz JF,
This triple mechanism distinguishes it from dual-agonist peptides like tirzepatide (GLP-1/GIP) and single-agonist compounds like semaglutide (GLP-1 only), making it the most broadly acting incretin-class compound currently under clinical investigation
We follow the best practices for manufacturing and comply with international safety, hygiene, and quality standards to deliver products that are safe, durable, and of the highest excellence
Encourages gut health*
Regulatory Status in 2026 BPC-157 has no FDA approval for human therapeutic use in the United States and is not eligible for compounding under 503B rules
Who should not use Lipo-B injections
US$ 24.91
US$ 25.85
US$ 28.04
